152P Efficacy and safety of relacorilant + nab-paclitaxel in patients aged ≥65 years with platinum-resistant ovarian cancer (PROC) in the phase III ROSELLA study (GOG-3073, ENGOT-ov72, APGOT-Ov10)

Journal article

Peer reviewed

A. Olawaiye, F. Derquin, N. Taylor, J-W. Kim, M. Scaranti, G. Valabrega, M.J. Messing, C.I. Diakos, G. Huygh, L. Willmott, …

ESMO open, Vol.11, p.108199

07/2026

Files and links (1)

url

https://doi.org/10.1016/j.esmoop.2026.108199View

Published (Version of record) Open

1 Record Views

Title: 152P Efficacy and safety of relacorilant + nab-paclitaxel in patients aged ≥65 years with platinum-resistant ovarian cancer (PROC) in the phase III ROSELLA study (GOG-3073, ENGOT-ov72, APGOT-Ov10)
Creators: A. Olawaiye - University of Pittsburgh School of Medicine
F. Derquin - Oncology Department, CARIO - Centre Armoricain de Radiothérapie, d’Imagerie Médicale et d’Oncologie, Plérin, France
N. Taylor - St. Luke's University Health Network
J-W. Kim - Seoul National University Hospital
M. Scaranti - Department of Gynaecology, Rede Américas Oncologia, Hospital 9 de Julho, Sao Paulo, Brazil
G. Valabrega - AO
M.J. Messing - Department of Gynecologic Oncology, Texas Oncology, Bedford, United States of America
C.I. Diakos - Royal North Shore Hospital
G. Huygh - Department of Medical Oncology, Belgium and Luxembourg Gynaecological Oncology Group (BGOG) and Onze-Lieve-VrouwzieKenhuis, Aalst, Belgium
L. Willmott - Gynecologic Oncology, Honor Health Research Institute, Phoenix, United States of America
et al.
Publication Details: ESMO open, Vol.11, p.108199
Publisher: Elsevier Ltd
Identifiers: 991006292369802656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article